Miro clears TGA audit ahead of Crohn’s disease trial
Miro Sciences has cleared a TGA manufacturing hurdle for its Crohn’s trial, with the regulator inspecting its partner’s facility ahead of a planned Phase 2 study for its StemSmart cell therapy.
Covered by 2 sources from Australia. First reported by The Sydney Morning Herald ·
How 2 newspapers cover this story
Miro clears TGA audit ahead of Crohn’s disease trial
Miro Sciences has cleared a TGA manufacturing hurdle for its Crohn’s trial, with the regulator inspecting its partner’s facility ahead of a planned Phase 2 study for its StemSmart cell therapy.
Miro clears TGA audit ahead of Crohn’s disease trial
Miro Sciences has cleared a TGA manufacturing hurdle for its Crohn’s trial, with the regulator inspecting its partner’s facility ahead of a planned Phase 2 study for its StemSmart cell therapy.
Coverage details
2 outlets from Australia are covering this story: The Sydney Morning Herald and The Age. The Sydney Morning Herald and The Age published it almost at the same time, on November 12, 2026.
Key names in the coverage: Miro Sciences, TGA, Crohn, Phase and StemSmart.
